Diffuse Large B Cell Lymphoma

These results demonstrate that a FISH-based assessment of MYC-, BCL2-, and BCL6-Rs is insufficient to capture the biological and diagnostic complexity of DLBCL. Targeted NGS provides structural and functional context that improves interpretation of rearrangements and supports a more refined genetic classification in routine practice.

ASCT was associated with the most durable survival among consolidation strategies after R-MVP induction. These findings, derived from a large real-world, multi-institutional cohort, support ASCT as the preferred consolidation for eligible patients while underscoring the heterogeneity of current practice and the need for prospective validation.

Given frailty, hypoalbuminemia, and prior anthracycline exposure, dose-reduced R-CHOP was initiated with careful limitation of cumulative doxorubicin. This case illustrates a rare presentation of very late, isolated extranodal DLBCL relapse manifesting as a cecal mass with genitourinary obstruction. It underscores the need to consider lymphoma in elderly patients with atypical gastrointestinal and urinary symptoms and highlights the importance of sustained clinical vigilance beyond the conventional 5-year surveillance period in long-term DLBCL survivors.

Notably, olaparib, a specific PARP-1 inhibitor, attenuated activation of parthanatos induced by curcumin alone or in combination with UVB. In summary, the present findings suggest that curcumin inhibits DLBCL cell proliferation through PARP1-mediated parthanatos and exhibits synergistic effects with UVB irradiation.

This offers novel perspectives on utilizing exosomal miRNAs for the early identification of DLBCL and their potential clinical application. However, given the small size of the discovery cohort, these estimates are presented as exploratory and should be confirmed in larger independent cohorts.

Curcumin inhibits the proliferation of DLBCL cells by activating the ferroptosis-related pathway, likely through modulating the ACSL4-SAT1-GPX4 axis. These findings provide a novel mechanistic insight into the anti-tumor activity of curcumin for DLBCL.

Stigmasterol significantly reverses RIT resistance in DLBCL by inhibiting MAPK1 phosphorylation and downregulating MDR protein expression. These findings provide new insights into overcoming RIT resistance and support the potential of stigmasterol as a therapeutic strategy for refractory DLBCL.

Malignant lymphoma should be considered in the differential diagnosis of acute obstructive symptoms, even when imaging findings suggest carcinoma. Prompt surgical intervention can facilitate definitive diagnosis and timely referral for systemic therapy in selected cases.

Our study demonstrates that EBV infection is required, but not sufficient, to upregulate SSTR2 in classic Hodgkin lymphoma, but not in other EBV-associated lymphomas. We also provide data to suggest that SSTR2 is associated with "higher-grade" germinal center-derived B-cell lymphomas in EBV-negative non-Hodgkin lymphomas.

There were high levels of Ki-67 proliferation indices in the aggressive lymphoma sub-types e.g. Diffuse Large B-Cell Lymphoma and T-cell lymphomas. The study helps to recommend a restricted yet cost-effective panel of IHC markers to attain reliable diagnosis and prognosis of lymphoma particularly in lower resource settings.

Key recommendations include the screening for high-risk features in MCL, use of the BOVen regimen (zanubrutinib, obinutuzumab, and venetoclax) for TP53-aberrant cases, and integration of chimeric antigen receptor T-cell therapy for patients with mantle cell lymphoma that is refractory to covalent Bruton tyrosine kinase inhibitors. For DLBCL, this article highlights the challenges in treatment sequencing and the role of circulating tumor DNA and minimal residual disease testing in monitoring disease progression. Overall, the conference describes the importance of ongoing research to refine management strategies and improve patient outcomes in lymphoma care, addressing the gaps in clinical practice where high-level evidence is lacking.

P1/2, N=200, Not yet recruiting, Merck Sharp & Dohme LLC